• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

byStudy Graphics | C.WuandConstance Wu
August 22, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma

#VisualAbstract: Melflufen plus dexamethasone showed superior progression-free survival over standard of care in multiple myeloma refractory to lenalidomide

1. bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) proteins, was shown to achieve objective response rates amongst a majority of 33 patients with refractory or relapsed multiple myeloma participating in a phase 1 safety trial. 
2. A majority of patients in this study were noted to have grade 3 hematologic adverse events. Non-hematologic adverse events were not as common and were often grade 2 or lower in severity.

Evidence Rating Level: 2 (Good)

Study Rundown: Multiple myeloma is an incurable plasma-cell cancer associated with the accumulation of immunoglobulin proteins. Previously proposed treatments for this disease have included monoclonal antibodies and immunomodulatory drugs, however these have not shown to be successful treatment methods and have eventually led to relapses amongst this patient group. Chimeric antigen receptor (CAR) T-cell therapy and anti-CD19 CAR T-cell therapy have proven to be promising agents for patients with leukemia and lymphoma. In this phase 1 study, researchers studied the safety of bb2121, an engineered compound which uses BCMA protein and autologous T-cell lentiviral vectors. The therapy was associated with high levels of hematologic-related adverse events including neutropenia, leukopenia, anemia, and thrombocytopenia, although most patients recovered neutrophil counts within 1 month. However, while other types of adverse events also occurred, the severity of non-hematologic adverse events were often grade 2 or below. Additionally, many patients showed an objective response to treatment, with almost half of patients experiencing a complete response.

While the sample size of this study was low and more safety and efficacy analyses are needed, these results show promise that bb2121 can be used to achieve the needed response efficacy rates for multiple myeloma treatment. Strengths of this study include its novel treatment approach and thorough evaluation of the treatment safety profile.

Click to read the study in NEJM

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: bb2121chimeric antigen receptor (CAR) T-cell therapymultiple myeloma
Previous Post

Quick Take: Association between incidence exposure to benzodiazepines in early pregnancy and risk of spontaneous abortion

Next Post

2 Minute Medicine Rewind May 27, 2019

RelatedReports

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
StudyGraphics

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

May 19, 2022
#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma
StudyGraphics

#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma

February 3, 2022
#VisualAbstract: Melflufen plus dexamethasone showed superior progression-free survival over standard of care in multiple myeloma refractory to lenalidomide
StudyGraphics

#VisualAbstract: Melflufen plus dexamethasone showed superior progression-free survival over standard of care in multiple myeloma refractory to lenalidomide

January 27, 2022
#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma
StudyGraphics

#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma

December 18, 2021
Next Post
Quick Take: Liver Fibrosis and Metabolic Alterations in Adults with Alpha1 Antitrypsin Deficiency Caused by the Pi*ZZ Mutation

2 Minute Medicine Rewind May 27, 2019

Quick Take: Effect of intranasal ketamine vs. fentanyl on pain reduction for extremity injuries in children: the PRIME randomized clinical trial

Rate of opioid prescribing in adolescents largely unchanged

#VisualAbstract: Association of Skipping Breakfast With Cardiovascular and All-Cause Mortality

#VisualAbstract: Association of Skipping Breakfast With Cardiovascular and All-Cause Mortality

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.